Axitinib meets PFS endpoint in RCC

Pfizer Inc. (NYSE:PFE) said twice-daily axitinib as second-line therapy met the primary endpoint of significantly improving progression-free survival vs. twice-daily Nexavar sorafenib in the Phase III...